BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 10937511)

  • 1. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
    Rosenstock J; Park G; Zimmerman J;
    Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
    Raskin P; Klaff L; Bergenstal R; Hallé JP; Donley D; Mecca T
    Diabetes Care; 2000 Nov; 23(11):1666-71. PubMed ID: 11092290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy].
    Pesić M; Zivić S; Radenković S; Velojić M; Dimić D; Antić S
    Vojnosanit Pregl; 2007 Apr; 64(4):247-52. PubMed ID: 17580534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
    Yki-Järvinen H; Dressler A; Ziemen M;
    Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.
    Ratner RE; Hirsch IB; Neifing JL; Garg SK; Mecca TE; Wilson CA
    Diabetes Care; 2000 May; 23(5):639-43. PubMed ID: 10834423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.
    Rosenstock J; Schwartz SL; Clark CM; Park GD; Donley DW; Edwards MB
    Diabetes Care; 2001 Apr; 24(4):631-6. PubMed ID: 11315821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F; Carabino JM; Vergara CM
    Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes--the glargine and aspart study (GLASS) a randomised cross-over study.
    Chatterjee S; Jarvis-Kay J; Rengarajan T; Lawrence IG; McNally PG; Davies MJ
    Diabetes Res Clin Pract; 2007 Aug; 77(2):215-22. PubMed ID: 17141354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR; Gilbert RE; Yue DK
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes.
    Pieber TR; Eugène-Jolchine I; Derobert E
    Diabetes Care; 2000 Feb; 23(2):157-62. PubMed ID: 10868824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes.
    Hershon KS; Blevins TC; Mayo CA; Rosskamp R
    Endocr Pract; 2004; 10(1):10-7. PubMed ID: 15251616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes.
    Home PD; Rosskamp R; Forjanic-Klapproth J; Dressler A;
    Diabetes Metab Res Rev; 2005; 21(6):545-53. PubMed ID: 16021649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
    Riddle MC; Rosenstock J; Gerich J;
    Diabetes Care; 2003 Nov; 26(11):3080-6. PubMed ID: 14578243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
    Ahmed AB; Mallias J; Home PD
    Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy.
    Albright ES; Desmond R; Bell DS
    Diabetes Care; 2004 Feb; 27(2):632-3. PubMed ID: 14747268
    [No Abstract]   [Full Text] [Related]  

  • 17. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes.
    Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the superiority of insulin glargine as basal insulin replacement by continuous glucose monitoring system.
    Wang XL; Lu JM; Pan CY; Mu YM; Dou JT; Ba JM; Wang X
    Diabetes Res Clin Pract; 2007 Apr; 76(1):30-6. PubMed ID: 16979255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.
    Roach P; Bai S; Charbonnel B; Consoli A; Taboga C; Tiengo A; Bolli G;
    Clin Ther; 2004 Apr; 26(4):502-10. PubMed ID: 15189747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.